Streetbeat News

Products Services

NVO

Photys Therapeutics has entered a multi-year collaboration with Novo Nordisk to develop proximity-based therapeutics for cardiometabolic diseases using PHICS technology. The deal could be worth up to $186 million, including milestone payments and royalties.

Portfolio Pulse from

December 18, 2024 | 12:45 pm

HRMY

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) for potential violations of federal securities laws. This follows a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

December 18, 2024 | 12:45 pm

SNAP

Snap stock is upgraded from sell to buy due to a 6% price drop and potential gains from a possible TikTok U.S. ban. Snapchat could benefit from increased user engagement and is expanding its creator monetization program.

Portfolio Pulse from

December 18, 2024 | 12:45 pm

SILO

Silo Pharma has initiated a pharmacokinetic and tolerability study for its novel non-opioid pain therapeutic, SP-26, targeting chronic pain and fibromyalgia. This marks a key preclinical milestone for the company.

Portfolio Pulse from

December 18, 2024 | 12:45 pm

ARAY

Accuray Incorporated announced a study showing that its CyberKnife System is effective for treating brainstem metastases, a challenging condition. This adds to existing literature on its benefits for neurological treatments.

Portfolio Pulse from

December 18, 2024 | 12:45 pm

CRGO

Swiss WorldCargo partners with Freightos to enhance digital booking for air freight services on the WebCargo platform, expanding its digital presence in Europe, Asia, and the Americas.

Portfolio Pulse from

December 18, 2024 | 12:45 pm

DHS

The WisdomTree U.S. High Dividend ETF (DHS), launched on June 16, 2006, is a smart beta ETF providing exposure to the Large Cap Value category. The article discusses whether DHS is a strong ETF choice currently.

Portfolio Pulse from

December 18, 2024 | 12:30 pm

CGTX

Cognition Therapeutics announced positive Phase 2 results for CT1812 in treating dementia with Lewy bodies, showing improvements in behavior, function, cognition, and movement. The company plans to advance CT1812 into late-stage trials.

Portfolio Pulse from

December 18, 2024 | 12:30 pm

DTIL

Precision BioSciences has received approval in Hong Kong to expand its Phase 1 ELIMINATE-B trial for PBGENE-HBV, a gene editing therapy aimed at treating chronic hepatitis B.

Portfolio Pulse from

December 18, 2024 | 12:30 pm

KROS

Keros Therapeutics' stock has dropped significantly due to safety concerns in its Phase 2 TROPOS trial, but it is now trading at cash value. The company has a cash runway until Q4 2028, supported by a $200 million payment from Takeda, with potential for future milestone payments.

Portfolio Pulse from

December 18, 2024 | 12:30 pm